Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2018

View Archived Issues

FN-1501 identified as a novel FLT-3 and CDK inhibitor for the treatment of AML

NIAID initiates phase I study of HIV-1 vaccines

GSK initiates phase II study of SARM GSK-2881078 in patients with COPD

Shanghai Pharmaceuticals initiates phase Ia trial with B-001 in patients with NHL

Insmed submits NDA for ALIS for nontuberculous mycobacterial lung disease

FDA grants orphan drug designation to Scholar Rock's SRK-015 for SMA

Catalyst submits NDA for Firdapse for LEMS

Pharmacokinetics of anti-HIV agent GS-9131 explored in phase I study

European Commission approves expanded indication for Xgeva

EMA accepts cemiplimab MAA for cutaneous squamous cell carcinoma

Symic reports 12-month data from SHIELD trial of SB-030 in peripheral vascular disease

EMA accepts Dupixent submission in asthma

First phase I data presented for ACT-709478 in healthy volunteers

ETC-206, a new agent for hematological cancers

FDA grants accelerated approval to Blincyto for B-cell precursor ALL with minimal residual disease

Numerate patents novel FFAR4 agonists

Roche and Genentech divulge new JAK1 inhibitors

Calithera Biosciences identifies new CD73 inhibitors

FDA approves Leukine for H-ARS

Chinese researchers discover CDK4/6 inhibitors

Novartis targets kinetoplastid proteasome for Chagas disease, leishmaniasis

Sunovion submits NDA for APL-130277 to treat off episodes associated with Parkinson's disease

Albert Einstein College of Medicine patents MSC-derived microvesicles

Motif Bio initiates rolling NDA for iclaprim

Compugen and MedImmune sign cancer immunotherapy license agreement

FDA issues refusal to file letter for Alkermes' ALKS-5461 NDA

Taiwan Liposome submits IND for TLC-590

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.